OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.